Biomaterial Database

In vivo antileishmanial efficacy of miltefosine against Leishmania (Leishmania) amazonensis. 2014

María F García Bustos, and Alejandra Barrio, and Gabriela G Prieto, and Emma M de Raspi, and Rubén O Cimino, and Rubén M Cardozo, and Luis A Parada, and Matthew Yeo, and Jaime Soto, and Delfor A Uncos, and Cecilia Parodi, and Miguel A Basombrío

Instituto de Patología Experimental, Facultad de Ciencias de la Salud, Universidad Nacional de Salta. Av. Bolivia 5150 (4400), Salta Capital, República Argentina.

Leishmaniasis, a disease caused by parasites of the Leishmania genus, constitutes a significant health and social problem in many countries and is increasing worldwide. The conventional treatment, meglumine antimoniate (MA), presents numerous disadvantages, including invasiveness, toxicity, and frequent therapeutic failure, justifying the attempts at finding alternatives to the first-line therapy. We have studied the comparative long-term efficacy of MA against miltefosine (MF) in Leishmania infection in experimental mice. The criteria for efficacy evaluation were footpad lesion size, anti-Leishmania antibodies level, histopathology of the site of inoculation (right footpad, RFP), splenic index (SI), and the presence of parasites in RFP, spleen, and liver, determined by polymerase chain reaction (PCR). Swiss mice, infected with Leishmania (Leishmania) amazonensis were treated, at different time points (5 and 40 days after infection) with either MA or MF. The efficacy of MF was better than that of MA for inhibiting lesions and for reducing tissue damage and presence/load of amastigotes in spleen and liver. Moreover, early administration of MF produced a clear reduction in splenomegaly and was equal in reducing antibody titles in comparison with MA. Our results demonstrated that MF is an effective and safe therapeutic alternative for leishmaniasis by L. (L.) amazonensis and is more efficacious than MA.

UI	MeSH Term	Description	Entries
D007894	Leishmania mexicana	A parasitic hemoflagellate of the subgenus Leishmania leishmania that infects man and animals including rodents. The Leishmania mexicana complex causes both cutaneous (LEISHMANIASIS, CUTANEOUS) and diffuse cutaneous leishmaniasis (LEISHMANIASIS, DIFFUSE CUTANEOUS) and includes the subspecies amazonensis, garnhami, mexicana, pifanoi, and venezuelensis. L. m. mexicana causes chiclero ulcer, a form of cutaneous leishmaniasis (LEISHMANIASIS, CUTANEOUS) in the New World. The sandfly, Lutzomyia, appears to be the vector.	Leishmania (Leishmania) mexicana,Leishmania mexicana amazonensis,Leishmania mexicana mexicana,Leishmania leishmania mexicana,Leishmania leishmania mexicanas,Leishmania mexicana amazonenses,Leishmania mexicana mexicanas,Leishmania mexicanas,amazonenses, Leishmania mexicana,amazonensis, Leishmania mexicana,leishmania mexicana, Leishmania,mexicana amazonensis, Leishmania,mexicana mexicana, Leishmania,mexicana mexicanas, Leishmania,mexicana, Leishmania,mexicana, Leishmania leishmania,mexicana, Leishmania mexicana,mexicanas, Leishmania leishmania
D008297	Male		Males
D008536	Meglumine	1-Deoxy-1-(methylamino)-D-glucitol. A derivative of sorbitol in which the hydroxyl group in position 1 is replaced by a methylamino group. Often used in conjunction with iodinated organic compounds as contrast medium.	Methylglucamine
D009942	Organometallic Compounds	A class of compounds of the type R-M, where a C atom is joined directly to any other element except H, C, N, O, F, Cl, Br, I, or At. (Grant & Hackh's Chemical Dictionary, 5th ed)	Metallo-Organic Compound,Metallo-Organic Compounds,Metalloorganic Compound,Organometallic Compound,Metalloorganic Compounds,Compound, Metallo-Organic,Compound, Metalloorganic,Compound, Organometallic,Compounds, Metallo-Organic,Compounds, Metalloorganic,Compounds, Organometallic,Metallo Organic Compound,Metallo Organic Compounds
D010767	Phosphorylcholine	Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.	Choline Chloride Dihydrogen Phosphate,Choline Phosphate Chloride,Phosphorylcholine Chloride,Choline Phosphate,Phosphocholine,Chloride, Choline Phosphate,Chloride, Phosphorylcholine,Phosphate Chloride, Choline,Phosphate, Choline
D000077485	Meglumine Antimoniate	ANTIMONY salt of meglumine that is used in the treatment of LEISHMANIASIS.	Glucantime,N-Methylglucamine Antimonate,N Methylglucamine Antimonate
D000818	Animals	Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA.	Animal,Metazoa,Animalia
D000981	Antiprotozoal Agents	Substances that are destructive to protozoans.	Schizonticides,Agents, Antiprotozoal
D013154	Spleen	An encapsulated lymphatic organ through which venous blood filters.
D016773	Leishmaniasis, Cutaneous	An endemic disease that is characterized by the development of single or multiple localized lesions on exposed areas of skin that typically ulcerate. The disease has been divided into Old and New World forms. Old World leishmaniasis is separated into three distinct types according to epidemiology and clinical manifestations and is caused by species of the L. tropica and L. aethiopica complexes as well as by species of the L. major genus. New World leishmaniasis, also called American leishmaniasis, occurs in South and Central America and is caused by species of the L. mexicana or L. braziliensis complexes.	Leishmaniasis, American,Leishmaniasis, New World,Leishmaniasis, Old World,Oriental Sore,American Leishmaniasis,Cutaneous Leishmaniases,Cutaneous Leishmaniasis,Leishmaniases, Cutaneous,New World Leishmaniasis,Old World Leishmaniasis,Sore, Oriental